SCHEMBL5374098

SCHEMBL5374098

O=C1Nc2ccc(CCCl)cc2C1=Cc1sccc1Br

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 2/20 0.61
LRRK2 Q5S007 3/20 0.42
RAF1 P04049 4/20 0.42
PSEN1 P49768 2/20 0.41
PSEN2 P49810 2/20 0.41
APH1B Q8WW43 2/20 0.41
NCSTN Q92542 2/20 0.41
APH1A Q96BI3 2/20 0.41
PSENEN Q9NZ42 2/20 0.41
MAP1LC3B Q9GZQ8 3/20 0.41
PDPK1 O15530 1/20 0.41
MAPT P10636 2/20 0.40
HTT P42858 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
PLK4 O00444 2/20 0.40
S1PR4 O95977 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HSP90AA1 P07900 1/20 0.40
ALOX12 P18054 1/20 0.40
S1PR1 P21453 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5365601 0.86 MEN1 (0.45) KDRLRRK2PDPK1MAPTHTT
SCHEMBL7139731 0.81 RET (0.42) KDRLRRK2RAF1PSEN1PSEN2
SCHEMBL5370082 0.79 LRRK2 (0.70) LRRK2RAF1PSEN1PSEN2APH1B
SCHEMBL5358302 0.78 MEN1 (0.49) KDRLRRK2RAF1PSEN1PSEN2
SCHEMBL5358971 0.78 MAP1LC3B (0.70) LRRK2RAF1PSEN1PSEN2APH1B
SCHEMBL7139897 0.77 MAPT (0.50) LRRK2RAF1PSEN1PSEN2APH1B
SCHEMBL6001467 0.76 KDR (1.00) KDRLRRK2RAF1PDPK1MAPT
SCHEMBL31060741 0.76 KDR (1.00) KDRLRRK2RAF1PDPK1MAPT
SCHEMBL5377096 0.76 PLK4 (0.55) KDRLRRK2RAF1PSEN1PSEN2
SCHEMBL5369248 0.76 RET (0.65) LRRK2RAF1PSEN1PSEN2APH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK KDR 239/4885LRRK2 289/4885RAF1 245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.